NEW DEVELOPMENTS IN MONOCLONAL-ANTIBODIES FOR CANCER-DETECTION AND THERAPY

被引：32

作者：

GOLDENBERG, DM

机构：

[1] Center for Molecularmedicine and Immunology, Garden state cancer center in Newark, New Jersey

来源：

CA-A CANCER JOURNAL FOR CLINICIANS | 1994年 / 44卷 / 01期

关键词：

D O I：

10.3322/canjclin.44.1.43

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Monoclonal antibodies have provided clinicians with an intriguing, target-specific approach to cancer management. Used alone or conjugated with drugs, toxins, or radionuclides, monoclonal antibodies have been shown to be useful in the detection and/or treatment of several cancers. Recent advances, such as the development of ''humanized'' antibodies, promise to increase their effectiveness even more. This article summarizes the status of the in vivo use of monoclonal antibodies for cancer detection and therapy.

引用

页码：43 / 64

页数：22

共 124 条

[41]

Allan SM, Dean C, Fernando I, Et al., Radioimmunolocalisation in breast cancer using the gene product of c‐erb B2 as the target antigen, Br J Cancer, 67, pp. 706-712, (1993)

[42]

Masui H, Kawamoto T, Sato JD, Et al., Growth inhibition of human tumor cells in athymic mice by anti‐epidermal growth factor receptor monoclonal antibodies, Cancer Res, 44, pp. 1002-1007, (1984)

[43]

Cuttitta F, Carney DN, Mulshine J, Et al., Bom‐besin‐like peptides can function as autocrine growth factors in human small‐cell lung cancer, Nature, 316, pp. 823-826, (1985)

[44]

Waldmann TA, Goldman CK, Bongiovanni KF, Et al., Therapy of patients with human T‐cell lympho‐trophic virus I‐induced adult T‐cell leukemia with anti‐Tac: A monoclonal antibody to the receptor for interleukin‐2, Blood, 72, pp. 1805-1816, (1988)

[45]

Wright PW, Bernstein ID, Serotherapy of malignant disease, Prog Exp Tumor Res, 25, pp. 140-162, (1980)

[46]

Harris DT, Mastrangelo MJ, Serotherapy of cancer, Semin Oncol, 16, pp. 180-198, (1989)

[47]

Janson CH, Tehrani M, Wigzell H, Et al., Rational use of biological response modifiers in hematological malignancies: A review of treatment with interferon, cytotoxic cells and antibodies, Leuk Res, 13, pp. 1039-1046, (1989)

[48]

Oi VT, Morrison SL, Chimeric antibodies, Bio‐Techniques, 4, pp. 214-221, (1986)

[49]

Jones PT, Dear PH, Foote J, Et al., Replacing the complementarity‐determining regions in a human antibody with those from a mouse, Nature, 321, pp. 522-525, (1986)

[50]

Shaw DR, Khazaeli MB, LoBuglio AF, Mouse/human chimeric antibodies to a tumor‐associated antigen: Biologic activity of the four human IgG subclasses, J Natl Cancer Inst, 80, pp. 1553-1559, (1988)

← 1 2 3 4 5 6 7 8 9 10 →